Ondansetro (Zofran, Zuplenz)
Supportive Care · Approved since 1991
Description
Ondansetron is a selective 5-HT3 receptor antagonist antiemetic medication used as supportive care in colorectal cancer treatment to prevent chemotherapy-induced and radiation-induced nausea and vomiting. It is particularly effective for managing acute nausea and vomiting that occurs within the first 24 hours after chemotherapy administration. In CRC patients, ondansetron is commonly used alongside standard chemotherapy regimens like FOLFOX or FOLFIRI to improve treatment tolerance and patient quality of life.
Mechanism of Action
Ondansetron works by selectively blocking serotonin (5-HT3) receptors located in the chemoreceptor trigger zone of the brain and on vagal nerve terminals in the gastrointestinal tract. By preventing serotonin from binding to these receptors, it effectively blocks the nausea and vomiting signals triggered by chemotherapy agents and radiation therapy.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Zofran, Zuplenz |
| Category | Supportive Care |
 Status | FDA Approved |
| Administration | IV, Oral |
| Year Approved | 1991 |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.